New combo aims to shrink tough colon tumors

NCT ID NCT05959356

First seen Jan 07, 2026 · Last updated Jun 16, 2026 · Updated 24 times

Summary

This study tests whether adding two extra drugs (envafolimab and a stronger chemo mix) to standard treatment can help people with a specific type of advanced colorectal cancer live longer without the disease getting worse. About 198 adults with left-sided, RAS/BRAF wild-type, MSS colorectal cancer that cannot be removed by surgery will be randomly assigned to one of two treatment groups. The goal is to see if the stronger combo improves tumor shrinkage and delays progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Cancer Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, 550000, China

    Contact Phone: •••-•••-••••

  • The First People's Hospital of Foshan

    RECRUITING

    Foshan, Guangdong, 528000, China

    Contact Phone: •••-•••-••••

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510655, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.